Gilead Sciences

Tweet this page
<
2016
2017
2018
2019
2020
2021
2022
>
Registration as it was on 21 Dec 2022
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

600,000€ - 699,999€

Financial year: Jan 2021 - Dec 2021

Lobbyists (Full time equivalent)

2.25 Fte (3)

Lobbyists with EP accreditation

2

High-level Commission meetings

9

Lobbying Costs over the years

  • Info

    Gilead Sciences   (GILD)

    EU Transparency Register

    258845020786-10 First registered on 23 Feb 2016

    Goals / Remit

    Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 38 countries worldwide.

    Main EU files targeted

    EU initiatives relevant to HIV/AIDS, Hepatitis B & C and oncology

    - ATMP Regulation
    - EU IP policy
    - EU research policy
    - EU trade policy
    - Health Systems Performance Assessment
    - Health Technology Assessment & Market Access
    - Industrial policy
    - Outcomes-based healthcare systems
    - Orphan Medicinal Products Regulation
    - Paediatric Regulation
    - Digital Health
    - Europe's Beating Cancer Plan
    - Blood, tissues and cells legislation
    - Sustainable Development Goals
    - EC Pharma Strategy
    - European Health Union
    - EU4Health
    - Re-opening of the general pharmaceutical legislation

    Address

    Head Office
    333 Lakeside Foster City
    California CA94404
    UNITED STATES
    EU Office
    Park Lane Culliganlaan 2
    Diegem 1831
    BELGIUM

    Website

  • People

    Total lobbyists declared

    3

    Employment timeLobbyists
    100%2
    25%1

    Lobbyists (Full time equivalent)

    2.25

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    2 accreditations were / are live (in bold) for the selected state of 31 Jan 2023

    Name Start date End Date
    Mr William SCHARF 12 Oct 2022 11 Oct 2023
    Mr Andrea Zanaglio 12 Oct 2022 11 Oct 2023
    Ms Claire Albano 31 Aug 2019 01 Sep 2020
    Mr Davis MARK 16 Oct 2018 01 Nov 2019
    Ms Claire Albano 12 Jun 2018 12 Jun 2019
    Mr Davis MARK 20 Jul 2017 07 Jul 2018
    Mr Julien Patris 20 Jul 2017 01 Dec 2017

    Complementary Information

    None declared

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Companies & groups

  • Networking

    Affiliation

    EFPIA: http://www.efpia.eu

    Europabio http://www.europabio.org

    EUCOPE http://www.eucope.org

    AMCHAM EU: http://www.amchameu.eu

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    Jan 2021 - Dec 2021

    Lobbying costs for closed financial year

    600,000€ - 699,999€

    Major contributions in closed year

    None declared

    Intermediaries for closed year

    NameAmount
    fipra public affairs 200,000€ - 299,999€

    Intermediaries for current year

    None declared

    Closed year Costs

    600,000€ - 699,999€

    Other financial info

    This estimate includes costs attributable to covered activities, including consulting fees, meeting costs and the pro rata salary and travel costs of Gilead Sciences' staff involved in representation to the European institutions, based on the proportion of employee time spent on these activities.

  • EU Structures

    Groups (European Commission)

    none

    Groups (European Parliament)

    N/A

    Other activities

    None declared

  • Meetings

    Meetings

    9 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't publish information about such meetings. All information below comes from European Commission web pages.

    • Date 11 Jun 2021 Location Brussels, virtual meeting
      Subject Exchange of views on joint procurement and scientific assessment of Remdesivir
      Cabinet Cabinet of Commissioner Stella Kyriakides
      Portfolio Health
      Commission
      • Stella Kyriakides (Commissioner)
    • Date 07 Dec 2020 Location virtual meeting
      Subject Exchange of views, update on Remdesivir
      Cabinet Cabinet of Commissioner Stella Kyriakides
      Portfolio Health
      Commission
      • Stella Kyriakides (Commissioner)
    • Date 16 Oct 2020 Location Brussels - virtual meeting
      Subject Exchange of views - update on Remdesivir
      Cabinet Cabinet of Commissioner Stella Kyriakides
      Portfolio Health
      Commission
      • Stella Kyriakides (Commissioner)
    • Date 09 Sep 2020 Location Phone call
      Subject Discussions/update on Remdesivir
      Cabinet Cabinet of Commissioner Stella Kyriakides
      Portfolio Health
      Commission
      • Stella Kyriakides (Commissioner)
    • Date 06 Jul 2020 Location Brussels
      Subject VC meeting: Exchange of views on the forthcoming Pharmaceutical Strategy
      Cabinet Cabinet of Commissioner Stella Kyriakides
      Portfolio Health
      Commission
      • Stella Kyriakides (Commissioner)
    • Date 06 May 2020 Location Brussels
      Subject VC meeting on remdesivir as a developmental medicine, the clinical trial programme, actions taken in respect of making remdesivir available via a compassionate use, Member States' needs and distribution should it receive market authorisation
      Cabinet Cabinet of Commissioner Stella Kyriakides
      Portfolio Health
      Commission
      • Stella Kyriakides (Commissioner)
    • Date 07 Apr 2020 Location Brussels
      Subject Discussion on medicines (potential treatments, production, clinical trials, access to results)
      Cabinet Cabinet of Commissioner Stella Kyriakides
      Portfolio Health
      Commission
      • Stella Kyriakides (Commissioner)
    • Date 25 Sep 2017 Location Brussels
      Subject Hepatitis B and C, HIV
      Cabinet Cabinet of Commissioner Vytenis Andriukaitis
      Portfolio Health &amp; Food Safety
      Commission
      • Arunas Vinciunas (Cabinet member)
    • Date 19 Jun 2017 Location Brussels
      Subject economic situation within the EU, investment climate, deepening of the EMU, social dimension of the European project, financial regulations and markets
      Cabinet Cabinet of Vice-President Valdis Dombrovskis
      Portfolio Euro and Social Dialogue, also in charge of Financial Stability, Financial Services and Capital Markets Union
      Commission
      • Elina Melngaile (Cabinet member)
      • Valdis Dombrovskis (Vice-President)
      Other Lobbyists
Download this datacard